SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Nicola Maurea(Cancer Institute (WIA)), Vincenzo Quagliariello(Cancer Institute (WIA)), Giuseppe Palma(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vincenzo Giordano(University of Alabama at Birmingham), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Isabella Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Séréna Grimaldi(Université Paris-Saclay), Francesca Bruzzese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Florio(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marino Scherillo, Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Laura Canale(Ospedale Versilia), Fabrizio Maurea(Federico II University Hospital)
Cited by 3
Related Papers
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
|The Lancet. Gastroenterology & hepatology|2020|602
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
A Review of the Treatment of Hip Dislocations Associated With Acetabular Fractures
|Clinical Orthopaedics and Related Research|2000|105